A Randomized, Double-blind, Placebo-controlled, Phase 2

Description

A Randomized, Double-blind, Placebo-controlled, Phase 2 Clinical Trial of Allisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)